Empagliflozin improves pressure-overload-induced cardiac hypertrophy by inhibiting the canonical Wnt/β-catenin signaling pathway

• Príomhchruthaitheoirí: Xun Yuan (Údar), Li Pan (Údar), Chi Zhang (Údar), Qiulian Zhu (Údar), Zexin Huang (Údar), Yuan Qin (Údar), Guiping Zhang (Údar), Zhimei Feng (Údar), Caixian Yang (Údar), Ning Hou (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Frontiers Media S.A., 2024-11-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

BackgroundEmpagliflozin (EMPA) is an SGLT-2 inhibitor that can control hyperglycemia. Clinical trials have indicated its cardio-protective effects against cardiac remodeling in diabetes or non-diabetes patients. However, the underlying molecular mechanisms of EMPA's cardio-protective effects re...